GoingToMeet

The continued emergence of antibacterial resistant strains of bacteria is placing an increasingly heavy burden on the world’s health services and is having a dramatic effect on global health.

There is a real need to develop new antimicrobials to combat this increasing threat; however as highlighted by the recent ECDC/EMEA Technical Report - The bacterial challenge: time to react – “Industry's pipeline contains very few new antibiotics active against multidrug-resistant bacteria. Without stimulating research and development into new antibiotics, an increasing number of infected patients will be without effective treatment".

This conference will bring you up to date with new and emerging products in the antimicrobials market, with a particular focus on antibacterials and antifungals and allow you to learn from and network with some of the leading individuals and organisations in this important area.

Key topics include:
• A global update on emerging antibiotic resistant pathogens
• Developments in the emerging global challenge of bacterial multi-drug resistance
• Tackling resistance in gram-negative bacteria
• Forming strategic alliances with large pharma to develop new antibacterials
• New approaches to fungal and protozoal infections
• Insights into novel therapies for overcoming resistance
Our expert speaker line-up includes:

• Dr Katsura Hata, Senior Researcher, Eisai Product Creation Systems
• Dr Alan Johnson, Clinical Scientist, Health Protection Agency
• Dr Graham Dixon, Senior Vice President Drug Discovery, Galapagos NV
• Dr Frank Koehn, Director – Biosynthetic and Discovery Analytical Chemistry, Pfizer
• Professor Peter Hawkey, Professor of Public Health Bacteriology, University of Birmingham and Health Protection Agency
• Dr Brian Noonan, Director of Bioscience, Infection Discovery, AstraZeneca